AtriCure Inc. (NASDAQ:ATRC) Director Elizabeth D. Krell sold 6,000 shares of AtriCure stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $15.93, for a total transaction of $95,580.00. Following the completion of the transaction, the director now owns 20,162 shares in the company, valued at approximately $321,180.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

AtriCure Inc. (NASDAQ:ATRC) opened at 16.24 on Monday. The stock’s 50 day moving average is $15.24 and its 200 day moving average is $15.52. AtriCure Inc. has a 12-month low of $13.44 and a 12-month high of $26.88. The stock’s market capitalization is $539.20 million.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, August 4th. The medical device company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.04. AtriCure had a negative net margin of 24.48% and a negative return on equity of 20.88%. The company had revenue of $39.70 million for the quarter, compared to analyst estimates of $39.84 million. During the same period in the prior year, the business earned ($0.18) earnings per share. AtriCure’s quarterly revenue was up 21.8% on a year-over-year basis. Analysts forecast that AtriCure Inc. will post ($1.16) EPS for the current year.

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its position in shares of AtriCure by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 134,237 shares of the medical device company’s stock valued at $1,896,000 after buying an additional 4,302 shares in the last quarter. Essex Investment Management Co. LLC raised its position in shares of AtriCure by 9.4% in the second quarter. Essex Investment Management Co. LLC now owns 79,076 shares of the medical device company’s stock valued at $1,117,000 after buying an additional 6,818 shares in the last quarter. Skylands Capital LLC raised its position in shares of AtriCure by 68.4% in the second quarter. Skylands Capital LLC now owns 92,597 shares of the medical device company’s stock valued at $1,308,000 after buying an additional 37,597 shares in the last quarter. Perkins Capital Management Inc. raised its position in shares of AtriCure by 1.1% in the second quarter. Perkins Capital Management Inc. now owns 85,100 shares of the medical device company’s stock valued at $1,202,000 after buying an additional 900 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in shares of AtriCure by 3.4% in the first quarter. Metropolitan Life Insurance Co. NY now owns 20,347 shares of the medical device company’s stock valued at $342,000 after buying an additional 661 shares in the last quarter. Institutional investors and hedge funds own 77.26% of the company’s stock.

Several research analysts have issued reports on the stock. BTIG Research restated a “buy” rating and issued a $19.00 price target (down previously from $34.00) on shares of AtriCure in a research report on Wednesday, August 10th. Needham & Company LLC restated a “buy” rating and issued a $20.00 price target (down previously from $23.00) on shares of AtriCure in a research report on Monday, August 8th. Piper Jaffray Cos. restated an “overweight” rating and issued a $17.00 price target (down previously from $22.00) on shares of AtriCure in a research report on Monday, August 8th. Canaccord Genuity set a $21.00 price target on shares of AtriCure and gave the stock a “buy” rating in a research report on Saturday, August 6th. Finally, JMP Securities set a $23.00 price target on shares of AtriCure and gave the stock a “buy” rating in a research report on Saturday, August 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $20.13.

AtriCure Company Profile

AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

5 Day Chart for NASDAQ:ATRC

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.